The Life Sciences team advised Quentis Therapeutics as it closed a $48 million Series A financing round to support the advancement of its lead program, a small molecule IRE1α inhibitor, into the clinic in 2019 and through clinical proof-of-concept. The financing was co-led by founding investor Versant Ventures and by Polaris Partners and the affiliated LS Polaris Innovation Fund. The syndicate also included AbbVie Ventures, Taiho Pharmaceutical Co., Ltd., Yonghua Capital, Alexandria Venture Investments and New York Ventures, the investment arm of Empire State Development.
Quentis Therapeutics is a preclinical stage biotechnology company that is translating novel biology into new therapeutic approaches to help more cancer patients benefit from immunotherapy.
For additional details on the financing, please read the press release.